866-997-4948(US-Canada Toll Free)

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 86 Pages

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Leishmaniasis (Kala-Azar) Overview 9
Therapeutics Development 10
Pipeline Products for Leishmaniasis (Kala-Azar) Overview 10
Pipeline Products for Leishmaniasis (Kala-Azar) Comparative Analysis 11
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies 12
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes 14
Leishmaniasis (Kala-Azar) Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Leishmaniasis (Kala-Azar) Products under Development by Companies 19
Leishmaniasis (Kala-Azar) Products under Investigation by Universities/Institutes 20
Leishmaniasis (Kala-Azar) Companies Involved in Therapeutics Development 21
Sanofi 21
Takeda Pharmaceutical Company Limited 22
Photopharmica Limited 23
Merck KGaA 24
iCo Therapeutics Inc. 25
Mologen AG 26
Advinus Therapeutics Ltd. 27
Dafra Pharma International Ltd. 28
aRigen Pharmaceuticals, Inc. 29
PolyTherics Limited 30
Leishmaniasis (Kala-Azar) Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
pentoxifylline - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
fexinidazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LEISH-F3 Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
amphotericin B - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MGN-1331 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Oleylphosphocholine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AS-605240 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Vaccine For Leishmania - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
amphotericin B NanoDisk - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Infectious Diseases - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule For Cutaneous Leishmaniasis - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule for Leishmaniasis - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
S-010269 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Compound-2d - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VL-2098 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Compound-26g - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pegylated amphotericin B - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
amphotericin b - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules For Leishmaniasis And Malaria - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Drug for Parasitic Diseases - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Neglected Disease Program 2 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules for Leishmaniasis and Oncology - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
methoxycoronaridine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CDRI-99/288 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Nitroimidazole Backup Compound - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Transfollicular Leishmaniasis Nanovaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ARA-03 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Leishmaniasis (Kala-Azar) Recent Pipeline Updates 73
Leishmaniasis (Kala-Azar) Dormant Projects 76
Leishmaniasis (Kala-Azar) Discontinued Products 77
Leishmaniasis (Kala-Azar) Product Development Milestones 78
Featured News & Press Releases 78
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis 78
Nov 11, 2013: Paladin Announces Extension of the Impavido PDUFA Date by Three Months 78
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 78
Dec 17, 2012: PATHs Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 79
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 80
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 80
Jan 09, 2012: Study Confirms New Strategy In Fight Against Infectious Diseases 81
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 82
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 83
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B 83

Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Table


Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2014 10
Number of Products under Development for Leishmaniasis (Kala-Azar) Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Comparative Analysis by Unknown Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Leishmaniasis (Kala-Azar) Pipeline by Sanofi, H1 2014 21
Leishmaniasis (Kala-Azar) Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 22
Leishmaniasis (Kala-Azar) Pipeline by Photopharmica Limited, H1 2014 23
Leishmaniasis (Kala-Azar) Pipeline by Merck KGaA, H1 2014 24
Leishmaniasis (Kala-Azar) Pipeline by iCo Therapeutics Inc., H1 2014 25
Leishmaniasis (Kala-Azar) Pipeline by Mologen AG, H1 2014 26
Leishmaniasis (Kala-Azar) Pipeline by Advinus Therapeutics Ltd., H1 2014 27
Leishmaniasis (Kala-Azar) Pipeline by Dafra Pharma International Ltd., H1 2014 28
Leishmaniasis (Kala-Azar) Pipeline by aRigen Pharmaceuticals, Inc., H1 2014 29
Leishmaniasis (Kala-Azar) Pipeline by PolyTherics Limited, H1 2014 30
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
Leishmaniasis (Kala-Azar) Therapeutics Recent Pipeline Updates, H1 2014 73
Leishmaniasis (Kala-Azar) Dormant Projects, H1 2014 76
Leishmaniasis (Kala-Azar) Discontinued Products, H1 2014 77

List of Chart


Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2014 10
Number of Products under Development for Leishmaniasis (Kala-Azar) Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Top 10 Target, H1 2014 32
Number of Products by Stage and Top 10 Target, H1 2014 33
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *